FDA Approves Moderna’s Next-Generation COVID-19 Vaccine For Adults 65 Or Older, At-Risk Patients

The AP (5/31) reported the FDA late Friday approved Moderna’s new low-dose COVID-19 vaccine, mNexspike, “for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus.” The vaccine “is a step toward next-generation coronavirus vaccines. It’s made in a way that allows for a lower dose – a fifth of the dose of its current COVID-19 vaccine, Spikevax – by refining its immune target.” Spikevax does not have mNexspike’s limits “and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall.”